On May 18, 2017 Nektar Therapeutics (Nasdaq: NKTR) reported its presence at the upcoming 2017 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, where it will share updated data from clinical studies of NKTR-214. ASCO (Free ASCO Whitepaper) will take place June 2-6, 2017 in Chicago (Press release, Nektar Therapeutics, MAY 18, 2017, View Source [SID1234519221]). Schedule your 30 min Free 1stOncology Demo! NKTR-214 is an investigational immuno-stimulatory therapy designed to expand specific cancer-fighting CD8+ effector T cells and natural killer (NK) cells directly in the tumor micro-environment and increase expression of PD-1 on these immune cells.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We look forward to providing updates on NKTR-214, including the first data from the PIVOT trial evaluating NKTR-214 in combination with nivolumab, as well as updated data from the monotherapy trial of NKTR-214, including I-O naïve RCC patients who received sequential checkpoint therapy following treatment with NKTR-214," said Mary Tagliaferri, M.D., Senior Vice President of Clinical Development at Nektar Therapeutics. "NKTR-214’s unique mechanism which selectively increases tumor-killing TILs, combined with its favorable safety profile and clinical activity, support our combination trials of NKTR-214 with existing checkpoint inhibitors such as nivolumab and atezolizumab, as well as other immuno-oncology mechanisms in development."
NKTR-214 targets CD122 specific receptors found on the surface of cancer-fighting immune cells in order to stimulate their proliferation. In clinical and preclinical studies, treatment with NKTR-214 resulted in expansion of these cells and mobilization into the tumor micro-environment.1,2,3 NKTR-214 has an antibody-like dosing regimen similar to the existing checkpoint inhibitor class of approved medicines.
The abstracts published in advance of the ASCO (Free ASCO Whitepaper) meeting which were made available yesterday on the ASCO (Free ASCO Whitepaper) website at www.asco.org include preliminary data only as of February 7, 2017. Updated and additional patient data from these trials will be presented at ASCO (Free ASCO Whitepaper).
Abstract 2545/Poster 37: "Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy."
Presenter: Chantale Bernatchez, Ph.D., The University of Texas MD Anderson Cancer Center
Poster Session: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Date and Time: Monday, June 5, 2017 – 8:00 a.m. – 11:30 a.m. CDT
Location: Hall A
Abstract e14040: "A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors." Diab, A., et al.
Publication abstract to be included online in the 2017 ASCO (Free ASCO Whitepaper) Annual Meeting Proceedings, a Journal of Clinical Oncology supplement.
Nektar will host an analyst and investor event with clinical investigators on Saturday, June 3, 2017 at 6:00 pm CDT in Chicago, IL during the 2017 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Meeting.
Presenters will include lead investigators from the NKTR-214 trial: Dr. Adi Diab, Assistant Professor, Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center, Dr. Nizar Tannir, Professor, Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center and Dr. Michael Hurwitz, Assistant Professor of Medicine (Medical Oncology) at Yale Cancer Center.
To register for the webcast of the event please visit: View Source
Seating is limited to attend the event in person, please contact [email protected] for more information.